Wednesday, October 26, 2011

BIO president calls on Congress to invest in innovation

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/djmeCduTtWCblxpTCidawyCicNvzXi

October 26, 2011
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • BIO president calls on Congress to invest in innovation
    BIO President and CEO James Greenwood, during the Biotech 2011 meeting in Philadelphia, criticized some of the cost-cutting measures that are being discussed in Washington, particularly those that would reduce Medicare drug payments. Greenwood said the measures would bring further hardships to biotech companies struggling through the regulatory approval process. Greenwood said lawmakers need to "invest in innovation" and build a "21st century FDA" in order for the U.S. to maintain competitiveness in the global life sciences industry. American City Business Journals/Philadelphia (10/25) LinkedInFacebookTwitterEmail this Story
With in-depth industry experience and expertise, GE Capital, Healthcare Financial Services’ dedicated Life Science Finance team has worked with more than 500 companies and provided over $2.5 billion in financing to the market. Click here to find out more and take our online poll.
  Health Care & Policy 
 
  • EU ban on ESC patents might speed up research
    The European Court of Justice's retroactive ban on patents for procedures involving the destruction of a human embryo might speed innovation as companies instead patent technologies, chemicals, equipment and growth media for turning embryonic stem cells into treatments, experts say. "If anything the ruling is an opportunity," said scientist Chris Mason of University College London. Nature News (10/24) LinkedInFacebookTwitterEmail this Story
  • Group of microRNAs inhibits cell reprogramming
    A group of microRNAs called miR-34 miRNAs inhibits cell reprogramming by blocking genes that play a role in pluripotency, according to a study published in Nature Cell Biology. The findings indicate that inhibiting miR-34 miRNAs may facilitate the transformation of somatic cells into induced pluripotent stem cells. The Scientist (free registration) (10/2011) LinkedInFacebookTwitterEmail this Story
John Jantsch invites you to go local
As customers continue to rely on the Web to help them screen local businesses, local businesses must take steps to ensure that they pop to the top of online searches. Duct Tape Marketing's John Jantsch offers strategies for local marketing success in this free white paper from American Express OPEN, How to Win at the Local Marketing Game. Download your free copy now, exclusively for SmartBrief readers.
  Company & Financial News 
 
  • Novartis restructuring, shifting resources to reduce costs
    Novartis is letting go of 2,000 U.S. and Swiss workers to reduce expenses during the next three to five years. The effort also includes shutting down a few sites and restructuring research-and-development operations. However, Novartis will add 700 jobs in China, India and other low-cost markets. PharmaTimes (U.K.) (10/25) LinkedInFacebookTwitterEmail this Story
LET’S GO DESIGN: Episode #5
In this episode of SolidWorks’ interactive web series, Jeremy moves closer to the final design of our Hot Rod Baby Buggy and also hot-wires the golf cart motor to show how the aluminum tracks perform flawlessly. Watch at LetsGoDesign.tv.
  Drug Development Basic Training 
  • Micro RNA Technology, Regulus article, published in October BP
     
    MicroRNAs and other intracellular therapies have often failed to move into the clinic in part because of the difficulty of targeting them to the proper cells and tissues with any reliability. Regulus is a biotech company that has developed a strategy for addressing this particular problem. This article describes their overall approach to drug delivery of microRNAs.

    Read the full article here.

    LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  Featured Content 
 

  Food & Agriculture 
  Industrial & Environmental 
  • Aventine educates first responders on ethanol safety
    Aventine Renewable Energy held training on anhydrous ammonia and ethanol safety last week. The seminars, at the company's corn-based ethanol facility in Pekin, Ill., were attended by about 100 people from fire departments, chemical companies, power plants and more. An Aventine official suggested other companies consider hosting similar training. "We've always tried to be a good neighbor," he said. EthanolProducer.com (10/25) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  Editor's Note 
  • Welcome to our new Wednesday Featured Content Provider, BioPharm International!
    BioPharm International magazine integrates the science and business of biopharmaceutical research, development and manufacturing. Every Wednesday, they'll bring BIO SmartBrief readers information about the transition from drug discovery to development in the new "Drug Development Basic Training" section. Check out the new section in today's issue and let us know what you think. LinkedInFacebookTwitterEmail this Story
  SmartQuote 
No one can possibly achieve any real and lasting success or get rich in business by being a conformist."
--J. Paul Getty,
American industrialist


LinkedInFacebookTwitterEmail this Story

 
 
This SmartBrief was created for jmabs1@gmail.com
 
Subscriber Tools
     
Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005
 
 
© 1999-2011 SmartBrief, Inc.® Legal Information

No comments: